Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

RANKL (receptor activator of NFkappaB ligand) is a membrane-associated osteoblastic molecule, and along with macrophage-colony-stimulating factor, is crucial for osteoclast formation. RANKL is known to be strongly expressed in osteoblasts and lymphoid tissues. We have sought to determine the skeleta...

Bibliografiset tiedot
Päätekijät:	Kartsogiannis, V, Zhou, H, Horwood, N, Thomas, R, Hards, D, Quinn, J, Niforas, P, Ng, K, Martin, T, Gillespie, M
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	1999

Samankaltaisia teoksia

Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Tekijä: Quinn, J, et al.
Julkaistu: (2000)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
Tekijä: Siamak Kazemi-Sufi, et al.
Julkaistu: (2024-09-01)

Activated T lymphocytes support osteoclast formation in vitro.
Tekijä: Horwood, N, et al.
Julkaistu: (1999)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Tekijä: Yosra Azizpour, et al.
Julkaistu: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Tekijä: Yosra Azizpour, et al.
Julkaistu: (2020-01-01)

Secreted frizzled-related protein inhibits TNFalpha- or RANKL-dependent osteoclast formation
Tekijä: Hausler, K, et al.
Julkaistu: (2003)

Canine soft tissue sarcomas: the expression of RUNX2 and karyopherin alpha-2 in extraskeletal (soft tissues) and skeletal osteosarcomas
Tekijä: Leonardo Leonardi, et al.
Julkaistu: (2024-02-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Tekijä: Martin Widschwendter, et al.
Julkaistu: (2015-10-01)

Secreted frizzled-related protein (sFRP-1) inhibits TNFalpha- or RANKL-dependent osteoclast formation.
Tekijä: Hausler, K, et al.
Julkaistu: (2002)

Potential role of vitamin D in prevention of skeletal and extraskeletal diseases in older people
Tekijä: Andrea Montagnani, et al.
Julkaistu: (2015-11-01)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
Tekijä: Cheema, Raheem Ramzan
Julkaistu: (2021)

Yukmijihwang-Tang Suppresses Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Mediated Bone Loss
Tekijä: Sang-Yong Han, et al.
Julkaistu: (2021-12-01)

NF-kappaB-inducing kinase is dispensable for activation of NF-kappaB in inflammatory settings but essential for lymphotoxin beta receptor activation of NF-kappaB in primary human fibroblasts.
Tekijä: Smith, C, et al.
Julkaistu: (2001)

A case of minimal change disease after the administration of anti receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibody: a case report
Tekijä: Keisuke Horikoshi, et al.
Julkaistu: (2020-09-01)

Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?
Tekijä: Feldmann, M, et al.
Julkaistu: (2002)

Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway
Tekijä: Xiao-Feng He, et al.
Julkaistu: (2017-11-01)

Bu-Shen-Ning-Xin decoction: inhibition of osteoclastogenesis by abrogation of the RANKL-induced NFATc1 and NF-κB signaling pathways via selective estrogen receptor α
Tekijä: Wang L, et al.
Julkaistu: (2015-07-01)

Interleukin-7 Induces Osteoclast Formation via STAT5, Independent of Receptor Activator of NF-kappaB Ligand
Tekijä: Jin-Hee Kim, et al.
Julkaistu: (2017-10-01)

The system of osteoprotegrin (OPG)/ligand of NF-kB receptor activator (RANKL) in patients with diabetes mellitus, mediacalcinosis and obliteratingatherosclerosis of lower leg arteries
Tekijä: Марианна Viktorovna Yaroslavtseva, et al.
Julkaistu: (2009-03-01)

In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)
Tekijä: Georgia Melagraki, et al.
Julkaistu: (2018-07-01)

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)
Tekijä: Bruno Vincenzi, et al.
Julkaistu: (2024-06-01)

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study
Tekijä: Dured Dardari, et al.
Julkaistu: (2022-04-01)

<i>Eleutherococcus sessiliflorus</i> Inhibits Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Induced Bone Loss
Tekijä: Sang-Yong Han, et al.
Julkaistu: (2021-03-01)

Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Tekijä: Häusler, K, et al.
Julkaistu: (2004)

Sistema osteoprotegerin (OPG) -ligand retseptora-aktivatora yadernogo faktora kappa-V (RANKL) pri diabeticheskoy neyroosteoartropatii i obliteriruyushchem ateroskleroze arteriy nizhnikh konechnostey
Tekijä: Марианна Viktorovna Yaroslavtseva, et al.
Julkaistu: (2007-06-01)

Calcifediol in the management of vitamin D deficiency-related skeletal and extraskeletal diseases: overview and clinical cases
Tekijä: Enrique Casado, et al.
Julkaistu: (2023-09-01)

Models of neuroinflammation for the assessment of kappa-opioid receptor ligands
Tekijä: K. Yu. Kalitin, et al.
Julkaistu: (2023-05-01)

Pharmacology of Kappa Opioid Receptors: Novel Assays and Ligands
Tekijä: Chiara Sturaro, et al.
Julkaistu: (2022-04-01)

Isopsoralen suppresses receptor activator of nuclear factor kappa-β ligand-induced osteoclastogenesis by inhibiting the NF-κB signaling
Tekijä: Wanda Zhan, et al.
Julkaistu: (2023-01-01)

Corrigendum: Interleukin-7 Induces Osteoclast Formation via STAT5, Independent of Receptor Activator of NF-kappaB Ligand
Tekijä: Jin-Hee Kim, et al.
Julkaistu: (2017-12-01)

Analysis of the Receptor Activator of NF-?B Ligand/Osteoprotegerin (RANKL/OPG) ratio as potential biomarker for infection-related bone destruction in pyogenic vertebral osteomyelitis
Tekijä: S. Lang, et al.
Julkaistu: (2024-01-01)

In Vitro Effects of <i>Weissella cibaria</i> CMU and CMS1 on Receptor Activator of NF-κB Ligand (RANKL)-Induced Osteoclast Differentiation
Tekijä: Geun-Yeong Park, et al.
Julkaistu: (2024-03-01)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
Tekijä: Marco Stellato
Julkaistu: (2022-09-01)

Extraskeletal Chondrosarcoma of Labium Majus
Tekijä: Arshad S. Khan, et al.
Julkaistu: (2011-01-01)

Extraskeletal Osteosarcoma of the Gluteal Region
Tekijä: Meena Jadhav, et al.
Julkaistu: (2015-10-01)

Extraskeletal Mesenchymal Chondrosarcoma of the Uterus
Tekijä: Yurimi Lee, et al.
Julkaistu: (2022-03-01)

Vitamin D and extraskeletal effects
Tekijä: Andra BURUIANĂ, et al.
Julkaistu: (2017-03-01)

Primary cutaneous extraskeletal osteosarcoma
Tekijä: Chia-Hsin Lu, et al.
Julkaistu: (2016-12-01)

Carbon Monoxide Inhibits Receptor Activator of NF-κB (RANKL)-Induced Osteoclastogenesis
Tekijä: Feng-Jen Tseng, et al.
Julkaistu: (2015-07-01)

Secreted Frizzled-related protein (sFRP-1) binds to RANKL to inhibit osteoclast formation.
Tekijä: Hausler, K, et al.
Julkaistu: (2001)